Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 19/20 | 0.49 |
| ▸ | UGCG | Q16739 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853356 | 1.00 | NTMT1 (0.49) | NTMT1UGCGCYP1A2CYP2D6 | |
| SCHEMBL2855643 | 0.94 | NTMT1 (0.49) | NTMT1UGCGCYP1A2CYP2D6 | |
| SCHEMBL2862222 | 0.94 | NTMT1 (0.49) | NTMT1UGCGCYP1A2CYP2D6 | |
| SCHEMBL2854402 | 0.92 | NTMT1 (0.47) | NTMT1UGCG | |
| SCHEMBL2854404 | 0.92 | NTMT1 (0.47) | NTMT1UGCG | |
| SCHEMBL2851481 | 0.92 | NTMT1 (0.47) | NTMT1UGCG | |
| Formic Acid SCHEMBL2854176 | 0.89 | NTMT1 (0.45) | NTMT1UGCG | |
| SCHEMBL2851715 | 0.87 | P2RX3 (0.41) | NTMT1CYP1A2CYP2D6 | |
| SCHEMBL2851720 | 0.87 | P2RX3 (0.41) | NTMT1CYP1A2CYP2D6 | |
| SCHEMBL2851660 | 0.85 | NTMT1 (0.47) | NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197658-A1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-05 | — | — | US | claimed |
| EP-1615647-B1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-01-20 | — | — | EP | claimed |
| EP-1828179-B1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AGAINST CNS-RELATED DISEASES | MEMORY PHARM CORP (US) | 2010-01-20 | — | — | EP | claimed |
| US-7625924-B2 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-01 | — | — | US | claimed |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20080153807-A1 | Pharmaceutical Use of Fused 1,2,4-Triazoles | NOVO NORDISK A/S (DK) | 2008-06-26 | — | — | US | claimed |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-27 | — | — | US | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060106008-A1 | Pharmaceutical use of fused 1,2,4-triazoles | NOVO NORDISK A/S (DK) | 2006-05-18 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| EP-0061350-A1 | Method of forming pattern | Hitachi, Ltd. (JP) | 1982-09-29 | — | — | EP | claimed |
| US-11809082-B2 | Pattern forming method and template manufacturing method | KIOXIA CORPORATION (JP) | 2023-11-07 | — | — | US | disclosed |
| US-20210302840-A1 | PATTERN FORMING METHOD AND TEMPLATE MANUFACTURING METHOD | KIOXIA CORPORATION (JP) | 2021-09-30 | — | — | US | disclosed |
| US-9192624-B2 | Medical material and method for manufacturing same | AJINOMOTO CO., INC. (JP) | 2015-11-24 | — | — | US | disclosed |
| EP-0082417-A2 | Selective etching method of polyimide type resin film | Hitachi, Ltd. (JP) | 1983-06-29 | — | — | EP | disclosed |
| EP-0061350-A1 | Method of forming pattern | Hitachi, Ltd. (JP) | 1982-09-29 | — | — | EP | disclosed |
| US-4243740-A | Light sensitive compositions of polymethyl isopropenyl ketone | TOKYO OHKA KOGYO KABUSHIKI KAISHA (JP) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106008-A1 | Pharmaceutical use of fused 1,2,4-triazoles | HSD3B1, HSD11B1, HSD11B2 | NTMT1 2314/4885UGCG 2007/4885CYP1A2 62/4885 |
| US-20080153807-A1 | Pharmaceutical Use of Fused 1,2,4-Triazoles | HSD3B1, HSD11B1, HSD11B2 | NTMT1 2314/4885UGCG 2007/4885CYP1A2 62/4885 |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | NTMT1 3155/4885UGCG 1172/4885CYP1A2 225/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | NTMT1 1578/4885UGCG 1346/4885CYP1A2 235/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | NTMT1 1578/4885UGCG 1346/4885CYP1A2 235/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | NTMT1 3155/4885UGCG 1172/4885CYP1A2 225/4885 |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA6 | NTMT1 927/4885UGCG 2056/4885CYP1A2 2614/4885 |
| US-20100197658-A1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HSD3B1, HSD11B2, HSD3B2 | NTMT1 3328/4885UGCG 970/4885CYP1A2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.